characteristics.text: SAMN33411803
characteristics.characteristic: External Id
characteristics.text: Biomedical Engineering, Columbia University
characteristics.characteristic: INSDC center name
characteristics.text: 2023-03-11T00:00:00Z
characteristics.characteristic: INSDC first public
characteristics.text: 2023-03-11T01:12:25.470Z
characteristics.characteristic: INSDC last update
characteristics.text: SRS16861511
characteristics.characteristic: INSDC secondary accession
characteristics.text: live
characteristics.characteristic: INSDC status
characteristics.text: Generic
characteristics.characteristic: NCBI submission model
characteristics.text: Generic.1.0
characteristics.characteristic: NCBI submission package
characteristics.text: SRS16861511
characteristics.characteristic: SRA accession
characteristics.text: A172, T98G and U87MG cells
characteristics.characteristic: cell line
characteristics.text: Human glioblastoma brain cancer cells
characteristics.characteristic: cell type
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: A172, T98G and U87MG cells
characteristics.characteristic: source_name
characteristics.text: sciPlex_4
characteristics.characteristic: title
characteristics.text: Cells were treated with increasing doses of the small molecules Alectinib, AZ628, AZD7762, BI-D1870, BM3-345541, DDR1-IN-1, Doxorubicin, GSK690693, Infigratinib, KU-5933, MK-2206, Nintedanib, Nutlin-3A, Palbociclib, PHA-767491, RIPA-56, Roscovitine, Salubrinal, Temozolomide, Temsirolimus, VE-821, Volasertib or dmso vehicle control in the absence or presence of trametinib co-exposure.
characteristics.characteristic: treatment